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Abstract 
Background: Validated diagnostic tools that are accurate, cost effective and acceptable to 
patients are required for disease stratification and monitoring in NAFLD.  
Aims: We investigated the performance and cost of multiparametric MRI alongside existing 
biomarkers in the assessment of NAFLD. 
Methods: Adult patients undergoing standard of care liver biopsy for NAFLD were 
prospectively recruited at two UK liver centres and underwent multiparametric MRI, blood 
sampling and transient elastography withing 2 weeks of liver biopsy.  Non-invasive markers 
were compared to histology as the gold standard.  
Results: Data were obtained in 50 patients and 6 healthy volunteers. Corrected T1 (cT1) 
correlated with NAFLD activity score (Rho=0.514, p<0.001). cT1, enhanced liver fibrosis 
(ELF) test and liver stiffness differentiated patients with simple steatosis and NASH with 
AUROC (95% CI) of 0.69 (0.50-0.88), 0.87 (0.77-0.79) and 0.82 (0.70-0.94) respectively and 
healthy volunteers from patients with AUROC (95% CI) of 0.93 (0.86-1.00), 0.81 (0.69-0.92) 
and 0.89 (0.77-1.00) respectively. For the risk stratification of NAFLD, multiparametric MRI 
could save £150,218.00 per 1000 patients compared to biopsy. Multiparametric MRI did not 
discriminate between individual histological fibrosis stages in this population (p=0.068). 
Conclusions: Multiparametric MRI accurately identified patients with steatosis, stratifies 
those with NASH or simple steatosis and reliably excludes clinically significant liver disease 
with superior negative predictive value (83.3%) to liver stiffness (42.9%) and ELF (57.1%). 
For the risk stratification of NAFLD multiparametric MRI was cost effective and, combined 
with transient elastography, had the lowest cost per correct diagnosis. 
  Page 6 of 49 
 
 
Keywords: Non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; hepatic fibrosis; 
magnetic resonance T1 mapping, cost effectiveness. 
 
   
  Page 7 of 49 
 
Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is an important and growing clinical concern 
associated with the increasing prevalence of obesity, type 2 diabetes, hypertension and 
dyslipidaemia. With the global prevalence of NAFLD estimated at 25.24%,1 effective 
strategies are required to ensure optimal risk stratification of patients in order that appropriate 
treatment is both offered and developed. As an umbrella term, NAFLD encompasses two 
main clinico-pathological entities: simple steatosis and non-alcoholic steatohepatitis (NASH). 
These conditions have distinct clinical significance and prognosis. Simple steatosis indicates 
hepatic steatosis without inflammation and whilst simple steatosis has been shown to increase 
mortality from cardiovascular disease, natural history studies indicate that simple steatosis 
leads to little or no progression of fibrosis and no increase in liver related mortality.2, 3 In 
contrast, NASH is characterised histologically by hepatocyte ballooning and lobular 
inflammation, culminates in cirrhosis in up to 20%4 and carries a hepatocellular carcinoma 
risk of 5.29 cases per 1,000 person years.1 
 
The majority of liver related morbidity and mortality in NAFLD is secondary to the 
complications of advanced fibrosis and fibrosis stage predicts clinical outcome.5-7 This offers 
valuable prognostic information to patients and their clinicians. In addition to fibrosis staging, 
distinguishing between simple steatosis and NASH is highly relevant for risk stratification in 
clinical practice and the enrichment of interventional trial populations.  
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Presently, the staging of NAFLD is largely dependent on interpretation of liver biopsy 
specimens, with the inherent challenges of procedural complications, cost, patient 
acceptability and sampling error.8 Alternative approaches to biopsy have been sought across 
liver disease aetiologies and include serum markers of fibrosis such as the Fibrosis-4 score, 
NAFLD fibrosis score, Enhanced Liver Fibrosis (ELF) test (iQur Limited, London, UK)9 and 
imaging technologies based on transient elastography10 and magnetic resonance imaging 
(MRI).11 Many of these non-invasive techniques have acquired a role in routine clinical 
practice. To date for example, National Institute for Health and Clinical Excellence guidance 
for NAFLD recommends ELF as a risk stratification tool, and in the National Institute for 
Health and Clinical Excellence guidance on cirrhosis; transient elastography is recommended 
for staging of fibrosis.12, 13  
 
As diagnostic tests evolve and clinical and trial strategies change, comparative evaluation of 
novel technologies is critically important for users.  We sought to determine how a novel 
quantitative liver MRI technology performed in terms of utility and comparative 
effectiveness, in the assessment of a prospective cohort of patients with NAFLD having 
routine liver biopsy as standard of care. We subsequently used the data to assess the potential 
cost effectiveness of this technique to understand whether this added investigation would 
reduce the cost burden of liver biopsy.  
 
Our study was an academic led, funded, and delivered evaluation of a proprietary algorithm - 
LiverMultiscan™ (Perspectum Diagnostics Ltd. Oxford, UK), a multiparametric MRI 
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technology used to quantify liver fat, iron and fibro-inflammatory injury by proton density fat 
fraction, T2* mapping and corrected T1 (cT1)14 mapping, respectively. T1 as a biomarker of 
hepatic fibrosis is confounded by hepatic siderosis. cT1 uses a measurement of iron content 
(T2*) and a patented algorithm to correct for this confounding.11 cT1 of the liver has 
previously been reported to stage hepatic fibrosis in an unselected population of patients 
undergoing liver biopsy.11 The proton density fat fraction measured using a modified Dixon 
sequence is a well-established and accurate technique for the assessment of hepatic fat 
content.15-17 Iron concentration was estimated from T2* according to a previously determined 
model.18 We report our comparative evaluation of the ability of this quantitative MRI 
technology to identify patients with hepatic steatosis, differentiate those with simple steatosis 
from those with NASH, grade disease activity and stage hepatic fibrosis. We demonstrate 
maximal utility in the ability of multiparametric MRI to distinguish between patients at low 
risk and those at high risk of progressive disease.  
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Methods 
 
Study Participants 
Our prospective study was undertaken at the Queen Elizabeth Hospital Birmingham and 
Royal Infirmary of Edinburgh between February 2014 and September 2015. The study 
protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was 
approved by the National Research Ethics Service (West Midlands – The Black Country; 
Ref: 14/WM/0010). The study was registered with the International Standard Randomised 
Controlled Trial Number registry (ISRCTN39463479) and the National Institute of Health 
Research portfolio (15912). The study sponsor was the University of Birmingham. Male and 
female adult (≥18 years of age) patients booked for non-targeted liver biopsy for any 
indication were prospectively recruited to a validation study of LiverMultiScan™ ( currently 
being prepared for publication). Patients with a histologically confirmed diagnosis of NAFLD 
without secondary cause and without history of alcohol excess (men >21 UK units/week, 
women >14 UK units/week) were included in this sub-group analysis. Data on the indication 
for biopsy are included in the supplementary material. Exclusion criteria were: biopsy of a 
distinct focal lesion, inability to give fully informed consent and any contraindication to MRI. 
 
Healthy volunteers were recruited from staff and students at the University of Birmingham. 
Exclusion criteria were obesity (Body mass index (BMI) >30kg/m2), current or previous 
history of liver disease, significant medical co-morbidity, family history of liver disease, 
excess alcohol intake or any contraindication to MRI. All participants gave written, informed 
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consent and attended for a single study visit during which they underwent multiparametric 
MRI, transient elastography with FibroScanTM (Echosens, Paris, France), blood sampling and 
collection of clinical and demographic data. All study investigations were performed after a 4 
hour fast. Patients undertook their study visit in the 2 weeks prior to liver biopsy and healthy 
volunteers did not undergo liver biopsy. 
 
Study Investigations 
All MRI scans were performed at 3.0 Tesla on Siemens Verio MRI scanners (Siemens 
Healthcare GMBH, Erlangen, Germany). The MRI protocol does not require intravenous 
contrast and has been previously described.11 In brief, the participant lies supine with 3-lead 
ECG for cardiac gating. A combination of body matrix and spine matrix coil elements was 
used to acquire data. Following localisers and shimming, the sequences include: shortened 
modified Look Locker inversion (ShMOLLI) recovery sequence (T1 mapping), multi-
gradient-echo sequence (T2* mapping), modified Dixon sequence and proton magnetic 
resonance spectroscopy with the Stimulated Echo Acquisition Mode sequence. All data were 
acquired during diastole with breath held in expiration to minimise movement artefact. Maps 
were acquired in a transverse plane through the liver hilum using the same slice position for 
each sequence. The voxel for magnetic resonance spectroscopy was placed in the right lobe 
of the liver avoiding biliary and vascular structures. Details of the MRI sequence parameters 
are contained in the supplementary material. Due to an error in the MRI acquisition protocol, 
proton density fat fraction as measured by the Dixon sequence (PDFF-Dixon) could not be 
calculated for the first 12 data sets. At this point the error was identified and corrected. 
PDFF-Dixon was calculated reliably for the remaining participants. 
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Transient elastography was performed by trained operators (PJE and NM) in accordance with 
manufacturer’s guidelines and validated local clinical practice.19 The decision on using the M 
probe or XL probe was made by the automated probe selection tool incorporated into the 
FibroScanTM machine. Examinations were regarded as ‘possible’ if at least 10 valid readings 
could be recorded and ‘reliable’ if they contained at least 10 valid readings and had 
interquartile range (IQR) to median ratio ≤30% (Boursier’s criteria).20 At the start of the 
study the Controlled Attenuation Parameter was not available on the FibroScanTM XL probe. 
Controlled Attenuation Parameter on the XL probe was enabled during study recruitment so 
was recorded if available in addition to median liver stiffness. 
 
Blood samples were analysed routinely for markers of liver disease. Simple blood biomarker 
panels including aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, 
Fibrosis-4 (FIB-4) and NAFLD fibrosis score were calculated according to published 
formulae.21, 22 Serum was also analysed to determine the enhanced liver fibrosis (ELF) score. 
 
MRI data analysis and iron correction 
T1, T2* and PDFF-Dixon maps were analysed using LiverMultiscanTM software by a single 
operator (AHH) blinded to the clinical findings and biopsy results. A user defined region of 
interest of approximately 1.4cm3 was placed in a representative area of the right lobe of the 
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liver avoiding vascular and biliary structures on the T1, T2* and PDFF-Dixon maps. 
LiverMultiscanTM software then calculates a corrected T1 value (cT1).  
 
Magnetic resonance spectroscopy data were analysed by a single operator (RBF) blinded to 
the histology results. Proton density fat fraction measured with magnetic resonance 
spectroscopy  (PDFF-MRS) was calculated from the non-water-suppressed Stimulated Echo 
Acquisition Mode acquisition (5 measurements of 1 signal average) using totally automatic 
robust quantitation in nuclear magnetic resonance (TARQUIN) software to perform 
automated preprocessing and fitting of the fat/liver spectrum. 23 Visual quality control of 
fitted spectra was performed by a medical physicist with experience of in vivo Magnetic 
resonance spectroscopy. Poorly fitted spectra were excluded from the analysis. PDFF-MRS 
was defined by the equation: 
 
PDFF-MRS =
area under methylene (1.3ppm) peak 
area under methylene (1.3ppm) peak +  area under water peaks
 
 
Histological assessment 
Liver biopsy samples were taken with 16-gauge biopsy needles. Histology was assessed by 
experienced academic liver histopathologists blinded to the MRI, ELF and transient 
elastography findings. Biopsies that were less than 15 mm in length or that contained fewer 
than 11 portal tracts were regarded as inadequate for histological assessment and were 
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therefore excluded.24, 25 Fibrosis and steatosis were staged according to the system described 
by Kleiner et al.26, 27 and siderosis according the Scheuer grading system.28 
 
Biopsies were categorised as NASH based on the presence of lobular inflammation and 
hepatocyte ballooning.29 Overall disease activity was graded according to the NAFLD 
activity score.26 Biopsy sections were also stained with Picro-Sirius Red and morphometry 
used to determine the collagen proportionate area (%) as previously described.30 
 
Statistical analysis 
Statistical analysis was carried out using IBM SPSS Statistics for Windows version 22 (IBM 
Corp, Armonk, NY). Variables are summarised with mean ± standard deviation (SD) if 
normally distributed and with median and range if not normally distributed. Comparisons 
between patients and healthy volunteers were performed using independent samples t-tests, 
Mann-Whitney tests, or Fisher’s exact tests, as applicable.  Correlation between continuous 
variables was determined with Spearman’s correlation coefficient (Rho). Comparisons across 
variables with multiple groups were performed using Kruskal-Wallis tests for nominal 
variables, or Jonckheere–Terpstra tests for ordinal variables. Post-hoc pairwise comparisons 
between groups were performed using Dunn’s test. Diagnostic performance was compared by 
calculation of the receiver operating characteristic and determination of the area under the 
curve (AUROC) with 95% confidence intervals (CI). For all tests, a p-value <0.05 was taken 
to indicate statistical significance.  
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Decision analytic model 
A recent study investigated the potential cost savings of adding multi-parametric MRI to the 
NAFLD risk stratification pathway.31 A decision tree model was developed to compare the 
expected outcomes and costs associated with three potential risk stratification pathways for 
NAFLD: using transient elastography alone, using multiparametric MRI as an adjunct to 
transient elastography, and using multiparametric MRI alone. We repeated this analysis, 
using the data collected from our study, based on the risk stratification pathways detailed in 
supplementary figure 1. For each risk stratification pathway, failure rates of transient 
elastography and MRI were used as reported in the previous study31 and we presumed the 
failure rate of ELF to be negligible at 0%. Using the prevalence of NAFLD in the previous 
study cohort (58.8%) and the sensitivities and specificities of each test derived in this study 
(Table 8), the proportions of patients that would have been correctly and incorrectly stratified 
were then calculated for each pathway. The expected test results were used to estimate the 
number of biopsies that would have been performed for a cohort of 1,000 patients. The total 
cost of each pathway was then evaluated, by adding together the costs of the tests and 
biopsies (based on NHS tariff data contained in the recent National Institute for Health and 
Clinical Excellence guidelines12) that would have been required per 1,000 patients. This was 
then subtracted from the total cost that would result from performing biopsies on all patients, 
in order to estimate the cost savings of each pathway. The resulting value was divided by the 
number of correct diagnoses, in order to estimate the cost per correct diagnosis, which could 
then be compared to the cost of a biopsy.  
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Results 
 
Patient demographics 
Of 54 patients with NAFLD recruited into the study (whole study included 162 unselected 
liver biopsies) 50 had sufficient data for analysis. Three MRI data sets were unusable and 1 
biopsy was judged too small for reliable fibrosis assessment and so these 4 patients were 
excluded. Seven healthy volunteers were recruited. One healthy volunteer was subsequently 
excluded from analysis due to the discovery of abnormal liver biochemistry. The study flow 
chart is shown in supplementary figure 2. The characteristics of the 50 patients and 6 healthy 
volunteers are outlined in  
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Table 1. Comparisons between these groups found that the healthy volunteers were 
significantly younger (median 32 vs. 54 years, p=0.011), had significantly lower BMI and 
lower waist to hip ratio. Healthy volunteers were more likely to consume alcohol than 
patients but there was no difference in the median consumption of drinkers and no patient or 
healthy volunteer drank alcohol to excess. 
 
In 49/50 (98%) patients, transient elastography was possible (≥10 valid readings) and in 
47/50 (94%) was reliable by Boursier’s criteria.20 Non-reliable transient elastography 
examinations were excluded from further analysis. In 16/47 (34%) patients, transient 
elastography was measured with the M probe and the remainder with the XL probe. For all 
healthy volunteers, transient elastography was measured with the M probe and was reliable 
by Boursier’s criteria.  
 
Median (range) length of liver biopsy samples was 25 (15-50) mm. Median (range) collagen 
proportionate area was 5.3 (0.6-34.2) %. Collagen proportionate area correlated strongly with 
Kleiner fibrosis stage (p<0.001) (supplementary figure 3). The characteristics of the histology 
and distribution of fibrosis stages in the cohort are shown in Table 2. Twelve (24%) of the 
patients had simple steatosis and 38 (76%) had NASH.  
 
Grading of steatosis by multiparametric MRI 
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PDFF-Dixon data was available for 38/50 (76%) patients and all healthy volunteers. Median 
PDFF-Dixon for healthy volunteers, grade 1, grade 2 and grade 3 steatosis were 1.8, 6.6, 15.3 
and 21.4% respectively (p<0.001) (Figure 1A). PDFF-MRS was available for 43/50 (86%) 
patients and 5/6 (83%) healthy volunteers. Median PDFF-MRS for volunteers, grade 1, grade 
2 and grade 3 steatosis were 0.3, 11.3, 23.7, and 31.5% respectively (p<0.001) (Figure 1B). 
AUROC (95% CI) for the identification of steatosis (Brunt grade ≥1) for both PDFF-Dixon 
and PDFF-MRS was 1.00 (1.00-1.00). 
 
Controlled Attenuation Parameter was available in 24/50 (48%) patients and all healthy 
volunteers. Median Controlled Attenuation Parameter for healthy volunteers, grade 1, grade 2 
and grade 3 steatosis were 246, 331, 361, 344 dB/m respectively (p=0.002) (Figure 1C). 
AUROC (95% CI) for Controlled Attenuation Parameter for the identification of steatosis 
(Brunt grade ≥1) was 0.95 (0.87-1.00). 
 
Differentiation between NASH and simple steatosis by cT1 measurement 
Demographic characteristics and blood results presented in Table 3 showed no significant 
difference between patients with NASH and those with simple steatosis. cT1 showed a 
significant difference between simple steatosis and NASH and, although not validated for this 
purpose, liver stiffness and ELF also showed significant differences between patients with 
simple steatosis and those with NASH (Table 4). Whilst multiparametric MRI did 
differentiate between NASH and simple steatosis, the AUROC (95% CI) for cT1 0.69 (0.50-
0.88) was inferior to ELF 0.87 (0.77-0.79) and liver stiffness 0.82 (0.70-0.94) (Figure 2). 
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Grading of disease activity by cT1 measurement  
In patients with NAFLD, semi-quantitative assessment of hepatocyte ballooning showed a 
statistically significant correlation with cT1, liver stiffness, and ELF. Lobular inflammation 
was significantly correlated with liver stiffness and ELF  but not cT1. Overall assessment of 
disease activity (as defined by the total NAFLD activity score) showed significant correlation 
with cT1, liver stiffness and ELF . The strength of these correlations can be seen in Table 5 
and  graphically in Figure 3 with p-values from the Jonckheere–Terpstra test.  
 
AUROC (95% CI) to differentiate those with NAFLD activity score <5 and NAFLD activity 
score ≥5 was statistically significant for cT1, liver stiffness, ELF and FIB-4, 0.74 (0.59-0.88), 
0.74 (0.59-0.89), 0.74 (0.59-0.89) and 0.73 (0.58-0.88) respectively. Statistical significance 
was not reached by AST:ALT ratio and NAFLD fibrosis score 0.60 (0.43-0.77) and 0.63 
(0.47-0.77), respectively. 
 
Staging of liver fibrosis by cT1 measurement 
Mean (±SD) cT1 for healthy volunteers was 791 (±42) ms. For patients with NAFLD with 
F0, F1, F2, F3 and F4 fibrosis mean (±SD) cT1 was 882 (±141), 969 (±115), 985(±93), 1016 
(±97) and 997 (±86) ms respectively as can be seen in Figure 4. Statistically significant 
differences were demonstrated between healthy volunteers and F2 fibrosis (p=0.048) and F3 
fibrosis (p=0.003). However, cT1 showed no significant trend across the fibrosis stages 
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(p=0.068), with pairwise comparisons finding no evidence of significant differences between 
individual fibrosis stages in patients with NAFLD. As shown in Figure 5, there was no 
evidence of significant correlation between cT1 and collagen proportionate area in patients 
with NAFLD (Rho=0.142, p=0.324).  
 
In NAFLD patients there was a significant association between Kleiner fibrosis stage and 
ELF (p<0.001), Liver stiffness (n=47) (p<0.001), NAFLD fibrosis score (p=0.003), 
AST/ALT ratio (p=0.002) and FIB-4 (p=0.013) (Figure 4). Collagen proportionate area 
showed significant correlation with: ELF (Rho=0.404, p=0.004), liver stiffness (n=47) 
(Rho=0.511, p<0.001), NAFLD fibrosis score (Rho=0.306, p=0.030), AST/ALT ratio 
(Rho=0.453, p=0.001) and FIB-4 (Rho=0.292, p=0.039) (Figure 5).  
 
To diagnose clinically significant (defined as ≥F2) fibrosis in patients with NAFLD, the 
AUROC (95% CI) for ELF, liver stiffness, AST:ALT ratio, NAFLD fibrosis score and FIB-4 
were statistically significant; 0.90 (0.82-0.99), 0.90 (0.81-0.99), 0.78 (0.64-0.93), 0.72 (0.54-
0.89) and 0.69 (0.52-0.86) respectively. cT1 did not reach statistical significance with 
AUROC (95% CI) of 0.63 (0.45-0.81). To diagnose advanced (defined as ≥F3) fibrosis in 
patients with NAFLD, liver stiffness, ELF and NAFLD fibrosis score were statistical 
significant with AUROC (95% CI) of 0.88 (0.76-0.99), 0.80 (0.68-0.93) and 0.66 (0.50-0.82), 
respectively. AST:ALT ratio, cT1 and FIB-4 did not reach statistical significance with 
AUROC (95%CI) of 0.63 (0.47-0.79), 0.62 (0.46-0.78) and 0.61 (0.45-0.78), respectively.  
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Comparative utility of multiparametric MRI to exclude significant liver disease 
10/50 (20%) of patients in the cohort were classified as being at low risk for progressive liver 
disease. This was defined as simple steatosis without clinically significant (>F1) fibrosis. 
cT1, liver stiffness, ELF, AST:ALT ratio and NAFLD fibrosis score showed statistically 
significant differences between healthy volunteers, low risk patients and high risk patients as 
shown in  
 cT1 Liver 
stiffness* 
ELF 
Hepatocyte ballooning Rho=0.308 
(p=0.030) 
Rho=0.450 
(p=0.002) 
Rho=0.366 
(p=0.009) 
Lobular inflammation Rho=0.069 
(p=0.635) 
Rho=0.433 
(p=0.002) 
Rho=0.440 
(p=0.001) 
Total NAFLD activity 
score 
Rho=0.514 
(p<0.001) 
Rho=0.419 
(p=0.003) 
Rho=0.460 
(p=0.001) 
Correlations assessed with Spearman’s Rho 
Bold p-values are significant at p<0.05 
*Based on reliable scans only (n=47) 
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Table 6. The AUROC (95% CI) to differentiate the different groups is shown in Table 7, and 
confirmed effective utility of multiparametric MRI as well as liver stiffness and ELF to 
exclude liver disease, with cT1 having the highest AUROC for differentiation of NAFLD and 
healthy volunteers (0.93).  
 
Taking common cut-off values for the three best performing tests, sensitivity, specificity, 
negative predictive value and positive predictive value for the diagnosis of high risk patients 
were calculated and are shown in Table 8. Importantly, negative predictive values, 
suggesting those patients for whom biopsy could potentially be avoided, were substantially 
higher for cT1 (80.0-83.3%) compared to liver stiffness (39.1-42.9%) and ELF (26.3-57.1%). 
 
Cost analysis of non-invasive tests for the staging of NAFLD 
The results of applying the sensitivity and specificity described in this study to the previously 
published decision tree model using our cohort of patients with NAFLD are provided in 
Table 9.  The risk stratification pathways considered the use of each test individually and 
also the combination of transient elastography followed by multiparametric MRI. For 
example, the use of the “cT1 only” risk stratification pathway using a 875ms cutoff was 
estimated to reduce the number of biopsies required by almost half (reduction of 458 per 
1,000 patients). As a result, the estimated saving was £150,218 per 1,000 patients, relative to 
the pathway in which biopsies are performed on all patients. All of the pathways considered 
were found to be potentially cost saving, relative to biopsy alone, with the exception of ELF 
at the lower cut-off of 7.7. In addition, those pathways that combined transient elastography 
and multiparametric MRI provided additional cost savings over multiparametric MRI alone. 
For example, the estimated cost per correct diagnosis was £554.26 using cT1 with a cutoff of 
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875ms, which reduced to £307.92 in the pathway where this was preceded by liver stiffness 
(7.0kPa cutoff). 
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Discussion 
 
The global burden of NAFLD is increasing inexorably and validated non-invasive diagnostic 
tests are important for patients, clinicians and industry. This is not only the first independent 
validation study to assess the diagnostic accuracy of multiparametric MRI with 
LiverMultiscanTM in NAFLD, but also the first study to compare the performance and 
potential cost-effectiveness of this emerging methodology against more established non-
invasive biomarkers of liver disease.  In our prospectively recruited population we 
demonstrated the ability of multiparametric MRI to grade hepatic steatosis with a high degree 
of accuracy. Moreover, multiparametric MRI demonstrated accurate differentiation of 
patients with simple steatosis from those with NASH and also correlated in a highly 
significant manner with overall disease activity as defined by NAFLD activity score. 
However, in this cohort, multiparametric MRI did not predict the severity of histological liver 
fibrosis. Multiparametric MRI demonstrated the greatest negative predictive value for 
excluding significant liver disease in those with NAFLD.  
 
Identifying those patients with NAFLD requires accurate detection of steatosis. In clinical 
practice, steatosis is typically assessed by visual grading of standard liver ultrasound 
images.32 Although the sensitivity of ultrasound in detecting moderate and severe steatosis is 
good, there is wide interobserver and intraobserver variability.32  Other non-invasive 
techniques for steatosis assessment such as the Fatty Liver Index have moderate to good 
accuracy but are significantly confounded by fibrosis stage and are unable to monitor changes 
in steatosis.33, 34 PDFF-Dixon has been shown in this study to have excellent accuracy in 
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differentiating patients with steatosis on liver biopsy from healthy volunteers with AUROC 
of 1.0. PDFF-Dixon also correlated strongly with PDFF-MRS (Rho=0.975, p<0.001), which 
is widely regarded at the most accurate method for non-invasive quantification of liver fat.17, 
35 Comparison of the accuracy of PDFF-Dixon and Controlled Attenuation Parameter for the 
detection of steatosis must be made with caution due to the small numbers of patients in this 
study with both a PDFF-Dixon and Controlled Attenuation Parameter reading. Both 
techniques had very high accuracy for the detection of any steatosis. 
 
PDFF-Dixon demonstrated a clear, stepwise increase with advancing Brunt steatosis grade in 
patients with NAFLD suggesting that multiparametric MRI could be used as an accurate 
method of monitoring steatosis progression and regression and assessing the therapeutic 
response to lifestyle or drug interventions in the context of clinical trials. In this study, 
Controlled Attenuation Parameter did not demonstrate the same stepwise increase with Brunt 
grade observed with PDFF-Dixon measurement.  
 
A single test to reliably exclude NAFLD would be of considerable value in clinical practice. 
In this study multiparametric MRI showed a high degree of accuracy for differentiating 
between healthy volunteers and those with NAFLD with AUROC (95% CI) of 0.93 (0.86-
1.00). It should be recognised however, that the healthy volunteers and patients enrolled in 
this study were not well matched in terms of age, waist to hip ratio or BMI. Accepting this 
limitation, using a cT1 cut-off value of 875ms gave multiparametric MRI a sensitivity of 
88.0% with specificity of 100% for the detection of any liver disease. This was superior to all 
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other non-invasive tests. In addition, the negative predictive value for excluding any liver 
disease was substantially higher than those for the other non-invasive techniques. This 
indicates an opportunity to consider further work to establish the ability of multiparametric 
MRI to be used as a single one-stop comprehensive MRI examination to rule out significant 
liver disease.  
 
When used in a risk stratification pathway for people with NAFLD in whom biopsy is 
clinically indicated, these non-invasive tests could be cost-saving if applied as first line tests. 
Furthermore, the combination of transient elastography with multiparametric MRI would 
provide the lowest total cost and, because diagnostic accuracy is maintained, would result in a 
lower total cost per correct diagnosis. 
 
The differentiation of those with NASH from those with simple steatosis is also an important 
distinction in clinical practice as our current understanding of NAFLD recognises NASH as 
the harbinger of progressive fibrosis and hepatocellular carcinoma.2, 3, 36 Identifying 
individuals with NASH stratifies patients at risk of significant disease and may do so at an 
earlier stage than tests that reflect fibrosis alone.37 Detection of NASH guides decision 
making about clinical management and follow-up intensity and identifies patients who may 
be eligible for recruitment to clinical studies.38 To date, the differentiation of simple steatosis 
and NASH has been reliant on liver biopsy. Liver biopsy has low patient acceptability due to 
its invasiveness and associated risk. Liver biopsy is also prone to sampling error and 
interobserver variation of histological assessment. These factors reduce the suitability and 
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reliability of liver biopsy for disease stratification in NAFLD. Currently available methods to 
non-invasively differentiate NASH and simple steatosis are suboptimal. Conventional blood 
tests and imaging techniques have low accuracy for the differentiation of simple steatosis and 
NASH.38  
 
To determine the severity of disease, cT1 showed a highly significant, positive correlation 
with NAFLD activity score. The correlation between NAFLD activity score and cT1 was 
stronger than between NAFLD activity score and any other evaluated test, althought the 
authors acknowledge that these tests are not designed to assess disease activity. This indicates 
the potential utility of multiparametric MRI as a sensitive diagnostic tool to monitor changes 
in disease activity. A NAFLD activity score of ≥5 is frequently used as a criterion to enrich 
clinical trials with patients with more significant liver disease. The performance of cT1 to 
make this distinction was comparable to the other non-invasive markers evaluated in this 
study.  
 
Staging of fibrosis in NAFLD has been clearly shown to predict clinical outcomes 5-7 and 
thus is an important part of the assessment of patients with NAFLD in clinical practice and 
for inclusion in current late stage clinical trials. Additionally both cT1 and ELF have also 
been reported to have utility in predicting clinical outcomes.39, 40 In this cohort, cT1 did not 
predict fibrosis defined by either Kleiner stage or collagen proportionate area whereas the 
other non-invasive markers assessed in this study performed in line with published work.41, 42  
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The lack of correlation between cT1 and fibrosis in this study was unexpected as previous 
work by Banerjee et al. in unselected patients11 and by Pavlides et al. in patients with 
NAFLD43 has shown a clear correlation between cT1 and fibrosis stage. It may be that our 
study is underpowered to detect this correlation, however, in our study it appears that the 
influence of disease activity on cT1 has hampered the ability of cT1 to detect stage 
differences in fibrosis; larger studies are needed to explore this further. Figure 6 shows the 
heavy confounding of disease activity on fibrosis assessment in this cohort. When grouped by 
fibrosis stage, the only statistically significant difference in cT1 is between low and high 
NAFLD activity score in patients with early stage fibrosis. This identification of a group of 
patient with early stage fibrosis and less severe disease as graded by NAFLD activity score 
characterises a group of patients at low risk of progressive liver disease. As shown in Table 
8, cT1 had comparable sensitivity, specificity and positive predictive value to ELF and liver 
stiffness for the exclusion of significant disease (NASH or fibrosis ≥F1) but notably greater 
negative predictive value suggesting that multiparametric MRI can identify patients without 
significant liver disease with confidence. These patients would potentially not need further 
investigations.   
 
Our study was prospective and enrolled unselected consecutive patients across two sites.  The 
statistical power is limited by recruitment volume, which may have resulted in some of the 
more subtle associations between variables being missed. Despite this, our independently 
collected data confirms the opportunities for new non-invasive biomarkers in liver disease 
severity assessment.  Although liver biopsy remains the gold standard, as a comparator it has 
known limitations of sampling error and interobserver variation.25, 44  However, in our study 
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we demonstrated that semi-quantitative histology scores correlated strongly with collagen 
proportionate area and other biomarkers performed as per previous publications.  
 
In conclusion, multiparametric MRI with LiverMultiscanTM has the ability to identify patients 
with NAFLD and to quantify steatosis and overall disease activity (by NAFLD activity 
score). Additionally, it stratified between healthy volunteers and patients with NAFLD as 
well as between patients at low risk and those at high risk of progressive liver disease. When 
evaluated alongside existing biomarkers, we conclude that different non-invasive tests may 
provide complementary diagnostic information and prove cost-effective when incorporated 
into clinical pathways by avoiding unnecessary liver biopsies.  Multiparametric MRI was 
superior for the grading of steatosis, grading of NASH severity, and for excluding disease, 
but in this cohort was inferior for the staging of fibrosis. The potential application of 
multiparametric MRI in clinical and research settings thus remains of great interest and 
further studies in appropriate clinical populations will facilitate improved understanding of 
the opportunities for applying MR imaging in evaluation of liver disease. 
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Figure Legends 
 
Figure 1: Box plots showing the relationships between non-invasive and histological 
assessment of steatosis. A) PDFF-Dixon and Brunt steatosis grade (n=38), B) PDFF-MRS 
and Brunt steatosis grade (n=43), C) Controlled Attenuation Parameter and Brunt steatosis 
grade (n=24). Inter-group differences were assessed with post-hoc tests with values shown in 
the supplementary material. CAP: controlled attenuation parameter, HV: healthy volunteer, 
PDFF: proton density fat fraction. 
 
Figure 2: Receiver operating characteristic curve for the differentiation of patients with 
simple steatosis from those with NASH (n=47) for cT1, liver stiffness and enhanced liver 
fibrosis test. ELF: enhanced liver fibrosis test. 
 
Figure 3: Box plots showing the relationships between the individual components of the 
NAFLD activity score and non-invasive markers of liver disease. p-values are derived from 
the Jonckheere–Terpstra test. NAS: NAFLD activity score, ELF: enhanced liver fibrosis test. 
A. cT1 showed a significant association with hepatocyte ballooning and total NAFLD 
activity score but not with lobular inflammation (n=50). B. Liver stiffness showed a 
significant association with hepatocyte ballooning, lobular inflammation and total NAFLD 
activity score (n=47). C. ELF score showed a significant association with hepatocyte 
ballooning and lobular inflammation but not total NAFLD activity score (n=50). 
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Figure 4: Box plots showing the relationships between non-invasive markers of liver disease 
and Kleiner fibrosis stage in the study cohort. cT1 did not have a statistically significant 
association with Kleiner fibrosis stage for patients with NAFLD. Liver stiffness (n=47), ELF, 
NAFLD fibrosis score, AST:ALT ratio and FIB-4 had a statistically significant association 
with Kleiner fibrosis stage. p-values shown were determined by the Jonckheere–Terpstra test 
across patients with NAFLD only and exclude healthy volunteers. HV: healthy volunteer, 
ELF: enhanced liver fibrosis test, NFS: NAFLD fibrosis score. 
 
Figure 5: Scatter plots showing the relationships between non-invasive markers of liver 
disease and collagen proportionate area in the study cohort. cT1 did not have a statistically 
significant correlation with collagen proportionate area, assessed by Spearman’s rank 
correlation. All other biomarkers had statistically significant correlations with collagen 
proportionate area as shown. Liver stiffness (n=47), enhanced liver fibrosis test, NAFLD 
fibrosis score, AST:ALT ratio, FIB-4. ELF: enhanced liver fibrosis test, NFS: NAFLD 
fibrosis score, CPA: collagen proportionate area. 
 
Figure 6: Box plot showing the influence of overall disease activity (as assessed by NAFLD 
activity score) on cT1.  In patients with low stage fibrosis there was significant difference in 
cT1 between those with NAFLD activity score <5 compared to those with a NAFLD activity 
score ≥5. This distinction had a trend towards significance in higher stage fibrosis. NAS: 
NAFLD activity score. 
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Table 1: Baseline characteristics of patients with NAFLD and healthy volunteers. 
 
Patients 
n=50 
Healthy 
Volunteers 
n=6 p-Value 
Age (years) 54 (18-73) 32 (23-55) 0.011 
Male 28 (56%) 3 (50%) 1.000 
Caucasian 43 (86%) 6 (100%) 1.000 
BMI (kg/m2) 33.6 ±5.1 24.0 ±2.5 0.001 
waist to hip ratio    
Male  0.98 ±0.07 0.81 ±0.05 0.001 
Female 0.90 ±0.06 0.72 ±0.03 0.001 
Post-transplant 5 (10%) n/a - 
Type 2 diabetes 26 (52%) n/a - 
Hypertension 25 (50%) n/a - 
Dyslipidaemia 26 (52%) n/a - 
Smoking Status   1.000 
Non-smoker 26 (58%) 4 (67%) - 
Ex-smoker 15 (30%) 2 (33%) - 
Current smoker 6 (12%) 0 (0%) - 
Consume alcohol 13 (26%) 6 (100%) 0.001 
UK units/week* 8 (1-20) 13 (1-15) 0.701 
Data reported as mean ±SD, with p-values from t-tests; median (range), with p-values from 
Mann-Whitney tests; or n (%), with p-values from Fisher’s exact tests, as applicable. 
Bold p-values are significant at p<0.05 
*In patients that consume alcohol  
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Table 2: Liver histology characteristics of study participants 
Characteristic n % 
Kleiner Fibrosis Stage 
0 6 12% 
1 10 20% 
2 9 18% 
3 20 40% 
4 5 10% 
Diagnosis 
Simple steatosis 12 24% 
NASH 38 76% 
Brunt Steatosis Grade 
0 0 0% 
1 23 46% 
2 17 34% 
3 10 20% 
Lobular Inflammation (NAFLD 
activity score) 
0 11 22% 
1 23 46% 
2 15 30% 
3 1 2% 
Hepatocyte Ballooning (NAFLD 
activity score) 
0 10 20% 
1 15 30% 
2 25 50% 
Total NAFLD activity score 
0 0 0% 
1-2 9 18% 
3-4 16 32% 
5-6 22 44% 
7-8 3 6% 
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Table 3: Demographic, clinical and laboratory parameters showed no difference 
between patients with simple steatosis and NASH. 
 
NASH 
(n=38) 
Simple Steatosis 
(n=12) p-Value 
Age (years) 54 (18-73) 46 (23-69) 0.216 
Male 19 (50%) 9 (75%) 0.186 
Caucasian 34 (90%) 9 (75%) 0.337 
BMI (kg/m2) 34.2 ±4.8 31.6 ±5.7 0.125 
Type 2 diabetes 22 (58%) 4 (33%) 0.190 
Hypertension 20 (53%) 5 (42%) 0.742 
Hyperlipidaemia 21 (55%) 5 (42%) 0.514 
Consume alcohol 8 (21%) 5 (42%) 0.256 
 Alcohol intake (UK units/week)*  7 (1-20) 12 (2-16) 0.831 
Bilirubin (µmol/L) 11 (4-45) 15 (5-50) 0.318 
Aspartate transaminase (AST) (U/L) 38 (19-119) 41 (16-112) 0.526 
Alanine transaminase (ALT) (U/L) 53 (18-153) 74 (15-176) 0.707 
Alkaline phosphatase (ALP) (U/L) 94 (45-251) 76 (50-149) 0.114 
Gamma-glutamyl transferase (gGT) (U/L) 78 (22-381) 58 (21-547) 0.071 
Albumin (g/L) 45 ±4 46 ±4 0.477 
Fasting glucose (mmol/L) 6.3 (2.8-17.3) 5.6 (4.6-11.4) 0.111 
Cholesterol (mmol/L) 4.8 ±1.5 5.2 ±1.2 0.470 
Triglycerides (mmol/L) 2.0 (0.7-5.8) 1.4 (0.9-2.7) 0.099 
Ferritin (µg/L) 115 (10-689) 177 (45-346) 0.159 
Transferrin saturation (%) 24.3 (7.5-49.6) 30.5 (14.7-43.7) 0.080 
Creatinine (µmol/L) 73 (46-143) 77 (52-97) 0.225 
Platelet count (x109/L) 219 ±71 197 ±37 0.172 
Data reported as mean ±SD, with p-values from t-tests; median (range), with p-values from 
Mann-Whitney tests; or n (%), with p-values from Fisher’s exact tests, as applicable. 
*In patients that consume alcohol  
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Table 4: cT1, liver stiffness and ELF showed significant differences between those with 
simple steatosis and those with NASH. 
 NASH 
(n=38) 
simple steatosis 
(n=12) 
p-Value 
cT1 (ms) 1007 ±94 907 ±120 0.004 
Liver Stiffness (kPa)* 10.2 (4.9-27.7) 6.1 (3.6-9.1) <0.001 
ELF 9.3 ±1.0 7.8 ±0.8 <0.001 
AST:ALT ratio 0.76 (0.27-1.56) 0.62 (0.34-1.07) 0.077 
NAFLD fibrosis score -0.95 ±1.64 -1.78 ±1.99 0.150 
FIB-4 1.20 (0.40-5.80) 1.12 (0.38-4.61) 0.351 
Data reported as mean ±SD, with p-values from t-tests or median (range), 
with p-values from Mann-Whitney tests, as applicable. 
Bold p-values are significant at p<0.05 
*Based on reliable scans only (n=47) 
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Table 5: Correlations between non-invasive biomarkers and the components of the 
NAFLD activity score 
 cT1 Liver 
stiffness* 
ELF 
Hepatocyte ballooning Rho=0.308 
(p=0.030) 
Rho=0.450 
(p=0.002) 
Rho=0.366 
(p=0.009) 
Lobular inflammation Rho=0.069 
(p=0.635) 
Rho=0.433 
(p=0.002) 
Rho=0.440 
(p=0.001) 
Total NAFLD activity 
score 
Rho=0.514 
(p<0.001) 
Rho=0.419 
(p=0.003) 
Rho=0.460 
(p=0.001) 
Correlations assessed with Spearman’s Rho 
Bold p-values are significant at p<0.05 
*Based on reliable scans only (n=47) 
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Table 6: cT1, liver stiffness and ELF show significant differences between high risk 
patients, low risk patients and healthy volunteers. 
 High risk 
patients* 
(n=40) 
Low risk 
Patients** 
(n=10) 
Healthy 
volunteers 
(n=6) p-Value 
cT1 (ms) 1007 ±93 890 ±122 790 ±42 <0.001 
Liver Stiffness (kPa)† 9.9 (4.9-27.7) 6.1 (3.6-9.1) 4.5 (3.6-6.8) <0.001 
ELF 9.2 ±1.0 7.7 ±0.8 7.9 ±0.3 <0.001 
AST:ALT ratio 0.76 (0.27-1.56) 0.65 (0.34-1.07) 1.02 (0.86-1.67) 0.018 
NAFLD fibrosis score -1.05 ±1.66 -1.54 ±2.09 -2.90 ±0.62 0.047 
FIB-4 1.15 (0.38-5.80) 1.23 (0.53-4.61) 0.87 (0.55-0.98) 0.158 
Data reported as mean ±SD, with p-values from one-way ANOVA or median (range), with p-
values from Kruskal-Wallis tests, as applicable. 
Bold p-values are significant at p<0.05 
* Patients with either NASH or >F1 fibrosis 
** Patients with simple steatosis and ≤F1 fibrosis 
† Based on reliable scans only (n=53) 
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Table 7: cT1, liver stiffness and ELF and stratification of low and high risk patients 
 
Low risk patients* 
(n=10) 
vs 
High risk patients** 
(n=37) 
Healthy volunteers 
(n=6) 
vs 
All patients  
(n=47) 
Healthy volunteers 
and low risk 
patients (n=16) 
vs 
High risk patients 
(n=37) 
cT1 0.73 (0.53-0.93) 0.93 (0.86-1.00) 0.83 (0.69-0.96) 
liver stiffness† 0.82 (0.69-0.94) 0.89 (0.77-1.00) 0.86 (0.76-0.96) 
ELF 0.89 (0.80-0.99) 0.81 (0.69-0.92) 0.89 (0.81-0.98) 
AST:ALT ratio 0.64 (0.45-0.84) 0.82 (0.67-0.97)†† 0.52 (0.34-0.70)†† 
NAFLD fibrosis 
score 
0.55 (0.32-0.77) 0.79 (0.66-0.91) 0.64 (0.47-0.81) 
FIB-4 0.51 (0.31-0.71) 0.72 (0.59-0.85) 0.59 (0.43-0.75) 
Data reported as AUROC (95% CI) 
Bold values were significant at p<0.05 
* Patients with simple steatosis and ≤F1 fibrosis 
** Patients with either NASH or >F1 fibrosis 
† Based on reliable scans only 
††Inverse relationship, i.e. AST:ALT ratio was higher in the healthy volunteer group 
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Table 8: Sensitivity, specificity, positive predictive value and negative predictive value at commonly accepted cut-off values for 
the differentiation of low and high risk patients. 
  AUROC (95% CI) Cut-off Sensitivity Specificity PPV NPV 
Differentiation of 
low* and high 
risk** patients 
cT1  0.73 (0.53-0.93) 822 ms11 97.5% 40.0% 86.7% 80.0% 
  875 ms39 97.5% 50.0% 88.6% 83.3% 
LS 0.82 (0.69-0.94) 5.8 kPa45 89.2% 30.0% 82.5% 42.9% 
  7.0 kPa45 75.7% 60.0% 87.5% 40.0% 
  7.9 kPa45 64.9% 70.0% 88.9% 35.0% 
  9.0 kPa45 62.2% 90.0% 95.8% 39.1% 
ELF 0.89 (0.80-0.99) 7.79 92.5% 40.0% 86.0% 57.1% 
   9.89 30.0% 100.0% 100.0% 26.3% 
 cT1  0.93 (0.86-1.00) 822 ms 90.0% 83.3% 97.8% 50.0% 
Differentiation 
healthy volunteers 
and patients 
  875 ms 88.0% 100.0% 100.0% 50.0% 
LS 0.89 (0.77-1.00) 5.8 kPa 85.1% 66.7% 95.2% 36.4% 
  7.0 kPa 68.1% 100.0% 100.0% 28.6% 
ELF 0.81 (0.69-0.92) 7.7 86.0% 16.7% 89.6% 12.5% 
   9.8 24.0% 100.0% 100.0% 13.6% 
* Patients with simple steatosis and ≤F1 fibrosis 
** Patients with either NASH or >F1 fibrosis 
LS: liver stiffnes, PPV: positive predictive value, NPV: negative predictive value 
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Table 9: Cost and effectiveness of diagnostic pathways for patients with suspected NAFLD 
  
Overall outcome Per 1000 patients Total cost 
 Cut-off Correct Incorrect Fail 
Biopsies 
avoided 
Total cost (£) 
Cost Saving 
vs Biopsy (£) 
Per correct 
diagnosis (£) 
cT1 
822 ms 82.9% 12.1% 5.0% 381.9 538,345 101,265 649.57 
875 ms 88.3% 6.7% 5.0% 458.4 489,392 150,218 554.26 
liver stiffness 
5.8 kPa 63.6% 18.4% 18.0% 297.2 517,530 122,080 814.16 
7.0 kPa 66.6% 15.4% 18.0% 491.6 393,146 246,464 590.14 
ELF 
7.7 57.4% 42.6% 0.0% 151.1 654,010 -14,400 1138.43 
9.8 55.3% 44.7% 0.0% 858.9 201,322 438,288 363.97 
liver stiffness 
(5.8 kPa) + 
cT1 
822 ms 81.4% 15.0% 3.5% 
734.6 338,260 301,350 415.37 
875 ms 83.4% 13.1% 3.5% 
722.7 345,851 293,759 414.60 
liver stiffness 
(7.0 kPa) + 
cT1 
822 ms 76.8% 20.7% 2.5% 
841.1 242,309 397,301 315.60 
875 ms 77.1% 20.3% 2.5% 
848.7 237,488 402,122 307.92 
Assumed costs: Biopsy (£639.91), MRI (£143), liver stiffness (£68), ELF (£111.06). Overall outcome rates are derived from the 
data in Table 8, with the rate of correct and incorrect outcomes being the sum of the true positives and true negatives (correct), 
or the false positives and false negatives (incorrect), respectively, for the pathway. Costs for each diagnostic pathway include all 
predicted test and biopsy costs for a cohort of 1,000 patients. 
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